Cargando…
Multiple myeloma: the (r)evolution of current therapy and a glance into the future
Over the past 20 years, the regulatory approval of several novel agents to treat multiple myeloma (MM) has prolonged median patient survival from 3 to 8-10 years. Increased understanding of MM biology has led to advances in diagnosis, prognosis, and response assessment, and has informed the developm...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Fondazione Ferrata Storti
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7556665/ https://www.ncbi.nlm.nih.gov/pubmed/33054076 http://dx.doi.org/10.3324/haematol.2020.247015 |